anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To investigate whether the use of a pericapsular nerve group (PENG) block would reduce perioperative pain after arthroscopic therapy for femoroacetabular impingement syndrome (FAIS) and to examine opioid requirements and occurrence of postoperative nausea and vomiting (PONV).
METHODS: Between May 2022 and October 2022, patients (N = 68) undergoing arthroscopic surgery for FAIS were randomly allocated into 2 groups. The first group received an ultrasound-guided PENG preoperatively with 20 mL of 0.375% ropivacaine and standardized postoperative oral medication. The second group received a sham block preoperatively with 20 mL of 0.9% saline and standardized postoperative oral medication. The primary end point was pain scores (visual analog score [VAS], 0-10) during the first 24 hours postoperatively. To quantify clinical significance of outcome achievement for the VAS pain score, the minimal clinically important difference (MCID) was calculated using the half standard deviation method. The incidence of PONV as well as opioid usage (converted to morphine equivalent) within the first 24 hours were secondary outcomes.
RESULTS: Randomization and permission were successfully obtained from 68 participants. From the fifteenth postoperative hour, the PENG group reported significantly less postoperative pain than the control group (24th postoperative hour: VAS pain PENG group 1.3 ± 0.9 [0-3]; 95% confidence interval {CI} 0.4-1.2 vs the VAS pain control group 2.4 ± 1.6 [0-5]; 95% CI 1.4-4.7; P = .009). The VAS pain score threshold for achieving the MCID at 24 hours postoperative was defined as a decrease of 1.1. 27 patients (79%) in the PENG group and 22 patients (65%) in the control group were able to achieve MCID (P = .009). Opioid dosage and postoperative nausea did not differ significantly between groups (P = .987 and P = .655, respectively). Concomitant complications such as falls, hematomas, or weakened muscles did not occur in either group.
CONCLUSIONS: According to this study, a PENG block minimally reduced pain after arthroscopic treatment for FAIS between the 18th and 24th postoperative hours. The PENG group achieved significantly more often the pain VAS MCID. However, there was no proof that the PENG group consumed fewer opioids than the control group. Overall, PONV was found at a low and comparable rate.
LEVEL OF EVIDENCE: Level I, randomized controlled trial.
Brucine is a weak alkaline indole alkaloid with wide pharmacological activities and has been identified to protect against rheumatoid arthritis (RA) process. Circular RNAs (circRNAs) are also reported to be involved in the pathogenesis of RA. Here, we aimed to probe the role and mechanism of Brucine and circ_0139658 in RA progression. The fibroblast-like synoviocytes of RA (RA-FLSs) were isolated for functional analysis. Cell proliferation, apoptosis, invasion, migration, as well as inflammatory response were evaluated by CCK-8 assay, EdU assay, flow cytometry, transwell assay, and ELISA analysis, respectively. qRT-PCR and western blotting analyses were utilized to measure the levels of genes and proteins. The binding between miR-653-5p and circ_0139658 or Yin Yang 1 (YY1), was verified using dual-luciferase reporter and RNA pull-down assays. Brucine suppressed the proliferation, migration, and invasion of RA-FLSs, and alleviated inflammation by reducing the release of pro-inflammatory factors and macrophage M1 polarization. RA-FLSs showed increased circ_0139658 and YY1 levels and decreased miR-653-5p levels. Circ_0139658 is directly bound to miR-653-5p to regulate YY1 expression. Brucine treatment suppressed circ_0139658 and YY1 expression but increased YY1 expression in RA-FLSs. Functionally, circ_0139658 overexpression reversed the suppressing effects of Brucine on RA-FLS dysfunction and inflammation. Moreover, circ_0139658 silencing alleviated the dysfunction and inflammation in RA-FLSs, which were reverted by YY1 overexpression. Brucine suppressed the proliferation, migration, invasion, and inflammation in RA-FLSs by decreasing YY1 via circ_0139658/miR-653-5p axis.
The invention relates to a preparation method and application of chitobiose. The preparation method comprises the following steps of dissolving chitobiose in glacial acetic acid solution; adding hydrogen peroxide; heating and stirring until the temperature is 40-90 DEG C and incubating; precipitating with ethanol after reaction is finished; filtering; and drying filter residues to obtain the chitobiose. The prepared chitobiose is used for preparing medicines for suppressing 10 strains of tumor cells of 5 kinds of humanized tumors. Biological compatibility and tumor atagonistics activity of the chitobiose are utilized effectively. By analyzing antitumor activity of the chitobiose, development of anti-tumor medicaments is promoted. The invention is used for the field of anti-tumor medicines.
PROBLEM TO BE SOLVED: To obtain the subject agent composed of a propenylbenzene derivative having a specific structure as active component, little in irritation to the skin, excellent in percutaneous absorbefacient activity and capable of stimulating percutanesous adsorption of an active component when compounded in a composition for external use for skin. SOLUTION: This agent contains a propenylbenzene derivative of the formula [R is independently H or OR' (R' is a 1-4C alkyl which may form a CC bond with another R')] (preferably, elemicine, myristicin, dill apiole, nothoapile, etc.) as an active component. These compounds are obtained, for example, from a plant body of a labiate by the fractional purification, etc., of a distillate or an extract obtained by steam distillation or solvent extraction. These agents can exhibit absorbefacient effect especially in an external composition for skin in which a component which alone is hardly percutaneously absorbed is compounded as an active component. The compounding ratios of the agents in these compositions are preferably 0.01-20wt.%.
Platelets engage in HIV-1 infection by interacting with immune cells, which has been realized broadly. However, the potential interaction between platelets and CD8+ T cells remains unidentified. Here, treatment-naive individuals with HIV-1, complete immunological responders to antiretroviral therapy, and healthy controls were enrolled. First, we found that treatment-naive individuals with HIV-1 had low platelet numbers and high CD8+ T-cell counts when compared with complete immunological responders to antiretroviral therapy and healthy controls, leading to a low platelet/CD8+ T-cell ratio in peripheral blood, which could effectively differentiate the status of HIV-1 infection. Moreover, cytokines that may have been derived from platelets were higher in the plasma of people with HIV-1 despite viral suppression. Furthermore, we demonstrated that platelet-CD8+ T-cell aggregates were elevated in treatment-naive individuals with HIV-1, which positively correlated with HIV-1 viral load but negatively correlated with CD4+ T-cell count and CD4/CD8 ratio. Finally, we revealed that platelet-CD8+ T-cell aggregates correlate with enhanced activation/exhaustion and pyroptosis/apoptosis compared with free CD8+ T cells. Moreover, platelet-induced caspase 1 activation of CD8+ T cells correlated with IL-1β and IL-18 plasma levels. In brief, we reveal the importance of platelets in HIV-1 infection, which might secrete more cytokines and mediate CD8+ T-cell phenotypic characteristics by forming platelet-CD8+ T-cell aggregates, which are related to poor prognosis.
Adhesive Capsulitis is a common cause of shoulder pain and disability and also a condition involving glen humeral pain and loss of motion. It is characterized by significant restriction of both active and passive motion that occurs in the absence of a known intrinsic shoulder disorder. The intervention strategies for AC include a trial of conservative therapy followed by more invasive procedures.it may be primary-onset is generally idiopathic or Secondary- results from known cause. Clinically, patients may present with pain and mild restriction of movement which can lead to a gross loss of function predisposing factor or surgical event . it is most frequent in women, diabetic population and patient older than 40 years .It is described as having 3 stages. Stage Ⅰ involves pain (freezing or painful stage) and lasts from 3 to 9 months and is characterized by an acute synovitis of the glen humeral joint. Stage Ⅱ (frozen or transitional stage) includes pain and restricted movement and lasts from 4 to 12 months. Stage Ⅲ (thawing stage) involves painless restriction and lasts from 12 to 42 months. Contributing factors include diabetes mellitus, stroke, thyroid disorder, dupuytren disease, complex regional pain syndrome and metabolic syndrome.

Axillary Phonophoresis and Post isometric facilitation play a major role in the treatment of adhesive capsulitis so this trial was conducted to determine which one has superiority. this trial has three groups. two experimental and one control group. pain ,function, pressure pain threshold will be measured.
STUDY DESIGN This is a Phase I open- label single-dose study in subjects with significant COPD. This is an expanded safety cohort. The investigators will enroll a minimum of 30 subjects. 6 week data of FEV1, FEV1/FVC, DLCO and 6 min walking distance values will be collected in all patients who are enrolled in the study (Baseline and 6 weeks after). Prior to the stem cell treatment, the patient will be assessed for 6 weeks by pulmonary function tests and 6 min walk tests. Then, patients will receive the infusion of stromal vascular fraction cells containing the aADSC (single intravenous dose). The standard therapy of COPD patients will not be interrupted during the duration of the study. Safety will be monitored on an ongoing basis, and an interim safety review will be conducted by the Investigator(s) and Sponsor after the first 20 patients have been enrolled and treated.
New surfactants (I) comprise a polar saccharidal head, a spacer group comprising an ethylene glycol and/or propylene glycol polymer and a lipophilic residue. Surfactants of formula [Su-A ]n-X (I) are new. Su : a L-rhamnoside or L-fucoside group; A : a spacer group comprising a polymer of ethylene glycol and/or propylene glycol comprising 1-10 polyalkylene glycol residues, 1-10C amide, ester or polyhydroxyacid groups, 1-6C hydroxy groups or 1-6C carboxylic acid groups; n : 1-5; X : Lip comprising a lipophilic group comprising sterol, cannabinoid, retinoid, fatty acid, fat soluble vitamin or polyisoprenic hydrocarbon, or a group of formula (i), and at least one of R1-R6optionally aromatic 6-30C alkyl or cycloalkyl optionally including at least one ether, ester, amide, thioether, carbamate or thiocarbamate group and the others are H, and R1-R6 bond with Su-A. [Image] An independent claim is also included for cosmetic and/or dermatological compositions containing (I). ACTIVITY : Dermatological. No biological data is given. MECHANISM OF ACTION : None given.
A system and process for applying access groups for controlling data access, by a processor device. The process receives from a user a request to access data associated with a person from a file system, whereby the request invokes at least one software method. Next method interception is performed by matching the at least one software method. Group membership of the user and at least one group membership of the person is accessed. Determining if each of the following conditions of i) the user is a member of a specific group and ii) the specific group contains the person are verified. In response to the conditions being verified, the process sends the data to a user device to display to the user, otherwise denying the request to access data. Each group can have one or more criteria, which add patients to that group based on the conditions of those criteria.
In a two-year study in rats, triamcinolone acetonide caused no treatment-related carcinogenicity at oral doses up to 1 mcg/kg (less than the maximum recommended daily intranasal dose in adults and children on a mcg/m2 basis, respectively). In a two-year study in mice, triamcinolone acetonide caused no treatment-related carcinogenicity at oral doses up to 3 mcg/kg (less than the maximum recommended daily intranasal dose in adults and children on a mcg/m2 basis, respectively).

No evidence of mutagenicity was detected from in vitro tests (a reverse mutation test in Salmonella bacteria and a forward mutation test in Chinese hamster ovary cells) conducted with triamcinolone acetonide.

In male and female rats, triamcinolone acetonide caused no change in pregnancy rate at oral doses up to 15 mcg/kg (less than the maximum recommended daily intranasal dose in adults on a mcg/m2 basis). Triamcinolone acetonide caused increased fetal resorptions and stillbirths and decreases in pup weight and survival at doses of 5 mcg/kg and above (less than the maximum recommended daily intranasal dose in adults on a mcg/m2 basis). At 1 mcg/kg (less than the maximum recommended daily intranasal dose in adults on a mcg/m2 basis), it did not induce the above mentioned effects.
OBJECTIVES: Childhood overweight/obesity is a serious public health problem in the world today specially low-and-middle income countries like Ethiopia. This study aimed to assess the prevalence of overweight/obesity and associated factors among preschool children.
METHODS: A community-based cross-sectional study was conducted among preschool children aged 3-5 years in Arba Minch city from April to June 2022. A multistage sampling method was used to select 577 study participants. Data were collected using a structured and pretested questionnaire. A binary logistic regression model was used for analysis. An adjusted odds ratio (AOR) with a 95% confidence interval (CI) was used to assess the strength of the association.
RESULTS: The combined prevalence of overweight/obesity was 23.9% (95% CI: 20.5, 27.6). Age of 36-47 months, family size < five, watching TV/video for ≥2 h, and consuming sweet foods, were factors associated with being overweight/obese among preschool children.
CONCLUSION: Overweight/obesity was predicted by consuming sweet foods, long time TV/video watching, and large family size in the study area. Special attention should be given to child feeding practices and reducing sedentary lifestyles.
The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
Chronic heart failure (HF) is a syndrome with a poor prognosis and with a prevalence increasing steeply by patients' age. Studies indicate that there are large potentials for improving general practitioners' diagnosis and management of HF. We have designed an educational intervention aiming at improving GPs' diagnosis and management of HF.

Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD). Individual feedback reports will be sent each participant in the beginning and at the end of the study. Main outcomes measure is the proportion of HF patients prescribed an ACE-inhibitor (or an angiotensine receptor blocker) and a betablocker in combination. Baseline data will provide material for a descriptive, cross sectional study. Patient related outcomes in terms of HF-hospital admissions and all cause mortality will be obtained by record linkage with NorPD and the Norwegian Patient Registry. Included in the intervention group is also a sub-study using a pop-up programme to facilitate disclosure of non-diagnosed HF patients in own practice. Finally, we plan a questionnaire study (among GPs in intervention group and their HF-patients) to get more knowledge regarding diagnostic workup, quality of care, non-pharmacological issues, and chronic care management of HF.
Adult T Cell Leukemia/Lymphoma (ATL) is a lymphoproliferative disease associated with HTLV-1 infection, characterized by circulating malignant cells expressing the IL-2 receptor (CD25). Prognosis for patients with ATL remains poor despite advances in chemotherapy, with survival in leukemic patients ranging from six months to less than one year. Novel agents that are potent and specific for the tumor cells are urgently needed to improve overall survival and decrease toxicity in this dismal disease. One therapeutic approach would be to use immunotoxins (ITs). ITs utilize a potent toxin linked to a targeting moiety designed to maximize drug delivery to the tumor cells, thus avoiding the nonspecific toxicity of conventional chemotherapeutic agents. Imtox-25 is constructed using the RFT5 murine monoclonal antibody (Mab) coupled to deglycosylated ricin-A chain (dgA) via the heterobifunctional, thiol-containing crosslinker, 4\[(succinimidyloxy) carbonyl\]-ƒÑ-methyl-ƒÑ-(2 pyridyldithio) toluene (SMPT). Phase I and II clinical studies with Imtox-25 (RFT5.dGA) have been shown safety and efficacy in adult patients with Hodgkin¡¦s disease and a recommended Phase II dose has been established.. In vitro experiments using ATL cell lines and in vivo studies in a murine xenograft model have demonstrated significant activity of Imtox-25 in this disease. Based on these results, the investigators propose to conduct a phase II trial utilizing Imtox-25 in adults with relapsed or refractory ATL.
All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
Expanding on the usual treatment regimen, Semaglutide is administered through a subcutaneous injection once weekly over a period of 3 months. Initially, the dose is 0.25 mg for the first month, then increased to 0.5 mg for patients who could tolerate it in the second month, and finally raised to 1.0 mg for patients who still tolerated it in the third month.
Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
FIELD: organic chemistry, biochemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to new condensed thienopyrimidines of the formula (I)   and their physiologically acceptable salts acting as inhibitors of activity of phosphodiesterase V (PDE V) that can be used for treatment of cardiovascular system and for treatment and/or therapy of disorder of sexual potency. In compounds of the formula (I) R 1 , R 2  each means independently of one another hydrogen atom, OA or Hal; R 1  and R 2  in common mean also alkylene with 3-5 carbon atoms, -O-CH 2 -CH 2 -, -CH 2 -O-CH 2 -, -O-CH 2 -O- or -O-CH 2 -CH 2 -O-; X means R 4 , R 5  or R 6  substituted once with substituent R 7 ; R 4  means linear or branched alkylene with 1-10 carbon atoms; R 5  means cycloalkyl or cycloalkylalkylene with 5-12 carbon atoms; R 6  means phenyl or phenylmethyl; R 7  means COOH or COOA wherein A means alkyl with 1-6 carbon atoms; Hal means fluorine, chlorine, bromine or iodine atom. Invention relates also to method for preparing compounds of the formula (I). Method for preparing involves interaction of compound of the formula (II)   wherein X has above indicated values and L means Cl, Br, OH, SCH 3  or reaction esterified OH-group with compound of the formula (III)   wherein R 1  and R 2  have above indicated values followed by if necessary conversion of one residue X in the prepared compound of the formula (I) to another residue X by, for example, hydrolysis of ester group to COOH-group and/or conversion of compound of the formula (I) to one of its physiologically acceptable salts. EFFECT: improved preparing method, valuable medicinal and biochemical properties of compounds. 6 cl, 1 tbl, 14 ex
Disclosed herein are devices, apparatuses, and/or systems for delivering aerosolized fluorocarbons (FCs). The systems can include a container, an aerosolizer, and an introduction assembly. The aerosolizer can be flui dicaliy coupled to the container and configured to aerosolize fluids from the container. The introduction assembly can be fluidically coupled to the aerosolizer and configured to introduce aerosolized fluids into the pulmonary tissue of a subject. Methods include aerosolizing a FC using an aerosolizer, delivering the FC to the pulmonary tissue of the subject, and contacting the pulmonary tissue of the subject with the FC. Some embodiments include cooling the pulmonary tissue. Cooling the pulmonary tissue can provide a therapeutic benefit to a living subject or it can preserve the pulmonary tissue of a deceased subject for transplantation.
PD is a complex disorder, with motor as well as non-motor symptoms. Despite the complexity of PD, management of the disease is often 'monodisciplinary' since most patients are only treated by a neurologist. Stimulating compensatory strategies by allied health professionals might offer additional therapeutic relief, but this assumption is mainly based on theoretical arguments and expert opinion. Even less is known about the claim that a multidisciplinary team of multiple professionals active in complementary domains (e.g. physiotherapy, occupational therapy and speech therapy) is superior to management by each of these professionals alone.

This study anticipates to provide more insight in the clinical effectiveness and health care costs of multidisciplinary treatment in PD. Therefore, our multidisciplinary care concept (a comprehensive assessment by a dedicated multidisciplinary team and subsequent treatment by specifically trained health professionals) that is tailored to the patients' individual needs will be compared to usual care in terms of effectiveness and costs.